講演・口頭発表等 - 藤井　俊光

1. Ami Kawamoto, Toshimitsu Fujii, Ryuichi Okamoto. Serum leucine-rich alpha-2 glycoprotein is an accurate marker for endoscopic and histological healing in ulcerative colitis. JDDW2024 2024.11.01 Kobe_Japan

2. K Matsuoka, S Motoya, T Yamamoto, M Matsuura, T Fujii, S Shinzaki, Y Mikami, S Arai, J Oshima, Y Endo, H Yuasa, M Hoshi, K Sato, T Hisamatsu. Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data. DDW2024 2024.05.19 Walter E. Washington Convention Center_ Washington, D.C.

3. Hiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, Yasuo Suzuki, Mamoru Watanabe, Yoko Uchikawa, Shoichiro Goto, Go Fujimoto, Changliang Zhang, Toshifumi Hibi. Ozanimod as induction and maintenance therapy for ulcerative colitis: a randomized, double-blind, placebo-controlled study in Japan (J-True North). DDW2024 2024.05.19 Walter E. Washington Convention Center_ Washington, D.C.

4. Katsuyoshi Matsuoka, Satoshi Motoya, Takayuki Yamamoto, Minoru Matsuura, Toshimitsu Fujii, Shinichiro Shinzaki, Yohei Mikami, Shoko Arai, Junichi Oshima, Yutaka Endo, Hirotoshi Yuasa, Masato Hoshi, Keiko Sato, Tadakazu Hisamatsu. Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of effectiveness and safety data. 19th Congress of ECCO 2024.02.23 Stockholmsmässan_Stockholm

5. Katsuyoshi Matsuoka, Hiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, Yasuo Suzuki, Mamoru Watanabe, Yoko Uchikawa, Shoichiro Goto, Go Fujimoto, Changliang Zhang, Toshifumi Hibi. Ozanimod as a once-daily oral therapy for Japanese patients with ulcerative colitis: results from the induction period of a phase 2/3 study (J-True North). 19th Congress of ECCO 2024.02.23 Stockholmsmässan_Stockholm

6. N.Takatsu, T.Yamamoto, H.Nakase, S.Shinzaki, K.Watanabe, T.Fujii, R.Okamoto, K.Matsuoka, A.Yamada, R.Kunisaki, M.Matsuura, H.Shiga, S.Bamba, Y.Mikami, T.Shimoyama, S.Motoya, T.Torisu, T.Kobayashi, N.Ohmiya, M.Saruta, S.Yoshigoe, Y.Murata, T.Hisamatsu. Clinical features and surgical necessity rate of fistulisingperianal disease in newly diagnosed patients with Crohn's disease: Interim analysis of inception cohort registry study of patients with Crohn's disease (iCREST-CD). 19th Congress of ECCO 2024.02.23 Stockholmsmässan_Stockholm

7. Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, John Liu, Andrew Garrison, Edward V Loftus Jr. Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately to Severely Active Crohn’s Disease. ACG 2023 - American College of Gastroenterology 2023.10.20 Vancouver_Canada

8. B.Bressler, L.Peyrin-Biroulet, J.R.Allegretti, K.G.Huang, M.Germinaro, N.Shipitofsky, Y.Miao, H.Zhang, M.Bortlik, T.Hlavaty, T.Fujii, B.G.Feagan, B.E.Sands, A.Dignass on behalf of the QUASAR Investigators. The Efficacy of Induction Treatment With Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History. ACG 2023 - American College of Gastroenterology 2023.10.20 Vancouver_Canada

9. T. Fujii , S. Hibiya , H. Shimizu , A. Kawamoto , K. Takenaka , E. Saito , M. Nagahori , K. Ohtsuka , R. Okamoto. DUAL THERAPY WITH CAROTEGRAST (AJM300: ORAL α4 INTEGRIN ANTAGONIST) AND BIOLOGICS FOR REFRACTORY ULCERATIVE COLITIS. UEGW2023 2023.10.15 Copenhagen_Denmark

10. Minhu Chen, Xiang Gao, Kenji Watanabe, Toshimitsu Fujii, Jae Hee Cheon, Shu-Chen Wei, Dennis Teng, Ana P Lacerda, Valencia P Remple, Hiroshi Nakase. Efficacy of Induction Upadacitinib Therapy in East Asian Patients With Moderately to Severely Active Crohn’s Disease. UEGW2023 2023.10.15 Copenhagen_Denmark

11. B.Bressler, L.Peyrin-Biroulet, J.R.Allegretti, K.G.Huang, M.Germinaro, N.Shipitofsky, Y.Miao, H.Zhang, M.Bortlik, T.Hlavaty, T.Fujii, B.G.Feagan, B.E.Sands, A.Dignass on behalf of the QUASAR Investigators. The Efficacy of Induction Treatment With Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History. UEGW2023 2023.10.15 Copenhagen_Denmark

12. Shuij Hibiya, Takashi Fujii, Toshimitsu Fujii, Kazuo Ohtsuka, Ryuichi Okamoto. Severe COVID-19 is associated with risk of lower gastrointestinal bleeding. UEGW2023 2023.10.14 Copenhagen_Denmark

13. A. Kawamoto, K. Takenaka, S. Hibiya, Y. Kitazume, K. Ito, H. Shimizu, T. Fujii, E. Saito, K. Ohtsuka, R. Okamoto. COMBINING LEUCINE-RICH ALPHA-2 GLYCOPROTEIN AND FAECAL BIOMARKERS FOR ACCURATE MONITORING OF SMALL BOWEL ACTIVITY IN CROHN’S DISEASE. UEGW2023 2023.10.14 Copenhagen_Denmark

14. Marc Ferrante, Laurent Peyrin-Biroulet, Axel Dignass, David T. Rubin, Silvio Danese, Geert D'Haens, Kristina Kligys, Sofie Berg, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Toshimitsu Fujii, and Remo Panaccione. Clinical and Endoscopic Improvements with Risankizumab Induction and Maintenance Dosing Versus Placebo are Observed Irrespective of Number of Prior Failed Biologics. UEGW2023 2023.10.11 Copenhagen_Denmark

15. Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Edward V Loftus Jr. Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib. SGG Swiss congress 2023 2023.09.23 Interlaken_Switzerland

16. Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Lena Thin, Edward V Loftus Jr. Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib. AGW2023 2023.09.02 Brisbane_Australia

17. Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P. Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Edward V. Loftus Jr. Corticosteroid Discontinuation and Clinical Outcomes in Patients With Moderately to Severely Active Crohn’s Disease Treated With Upadacitinib. DDW2023 2023.05.09 Washington,D.C._USA

18. Marc Ferrante, Qian Cao, Toshimitsu Fujii, Astrid Rausch, Ezequiel Neimark, Alexandra Song, Kori Wallace, Kristina Kligys, Qing Zhou, Jasmina Kalabic, Brian Feagan. Patients with Moderate-to-Severe Crohn’s Disease with and without Prior Biologic Failure Demonstrate Improved Endoscopic Outcomes with Risankizumab: Results from Phase 3 Induction and Maintenance Trials Marc. DDW2023 2023.05.09 Washington,D.C._USA

19. M.C. Dubinsky, G. D’Haens, O. Dewit, P. Juillerat, R. Panaccione, T. Fujii, A.P. Lacerda, E. Dubcenco, S.Anyanwu, C. Doshi, M. Mallick, A. Garrison, J. Liu, E.V. Loftus Jr.. Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinib. 18th Congress of ECCO 2023.03.02 Copenhagen_Denmark

20. Marc Ferrante, Laurent Peyrin-Biroulet, Axel Dignass, David T. Rubin, Silvio Danese, Geert D'Haens, Kristina Kligys, Sofie Berg, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Toshimitsu Fujii, and Remo Panaccione. Clinical and Endoscopic Improvements with Risankizumab Induction and Maintenance Dosing Versus Placebo are Observed Irrespective of Number of Prior Failed Biologics. American College of Gastroenterology Annual Scientific Meeting 2022.10.25